

Candidate: Elected Member MD (2023-2025)



Sven Kili, MB, ChB, MRCS (Eng)

CEO

Antion Biosciences

United Kingdom

Summary of academic and professional background:

I trained as a Trauma and Orthopaedic Surgeon in the UK, preceded by my General Surgical training, also in the UK. I completed my Undergraduate Medical Training at Stellenbosch University Medical School in South Africa. This was followed by work in acute trauma services and Sports Trauma medicine before moving to the UK to specialise in surgical disciplines.

I started working in the cell and gene therapy space in 2001 as a practising surgeon, utilising various cell-based therapies in research and clinical practise. This progressed to leading clinical research as a clinical tutor for a large government sponsored clinical trial of cells vs no-cells for traumatic chondral defects, which had sites in the UK, Sweden and Norway.

Following my move from full-time clinical position to an industry role in 2005, I led the development of new technologies and surgical techniques in cell-based chondral surgery and assumed a company UK/ Ireland Regulatory role followed by a period as the EU QPPV (Qualified Person for Pharmacovigilance) for my company.

My next role was with Genzyme where I ended up heading all medical aspects of the Cell Therapy & Regen Med business with oversight of three cell therapies - Carticel, Epicel and MACI. In this role I oversaw the clinical development of MACI in the SUMMIT trial leading to the approval as the first combined ATMP. I also led the US medical organisation supporting the use of Carticel and Epicel and their improvements.

I later joined GSK as Head of Development for the CGT unit where I oversaw the development and all medical aspects of 8 Gene Therapies, including the submission, approval and launch of Strimvelis as the first ex-vivo Gene therapy ever, in addition to clinical development of MLD (now Libmeldy) and WAS therapies, translation of gene therapies for Beta-thal, SCD and MPS-1. I was responsible for all R&D, CMC, Clinical Dev and Med Affairs. Following the sale of the CGT business from GSK in 2018, I was made redundant and consulted for 3 years focussing on creating companies, clinical development planning & execution and general company strategic services.

This led me to working with Antion Biosciences, a company focussed on developing multiplex engineered allo and in vivo cell therapies. I joined Antion as CEO in 2021.

Affiliated professional and commercial associations and any perceived or potential conflict of interests:

1. Antion Biosciences - CEO
2. Saisei Investments - Member of Investment Committee
3. Sven Kili Consulting Ltd - Principal
4. ISCT - Co-Chair of BD & Finance Committee
5. CCRM - Member of the Board of Directors and Chair of the Investment Committee
6. ARM - Chair of Gene Therapy Advisory Committee
7. UCL - Visiting Professor and Chair of Steering committee for MSc in Manufacture & Commercialisation of Stem cell and gene therapies
8. BIA - Chair of Cell and Gene Therapy Advisory Committee
9. UK Innovation Hubs for Gene Therapy – Chair Hubs Steering Committee
10. LGC Corporation - SAB Member
11. ASGCT - Member of Patient Outreach Committee

List of top notable contributions to the field (e.g. publications, patents, reports, products advanced to clinical trial or regulatory approval, asset development, mergers, acquisitions, etc.) from the last 10 years:

1. Led the development, approval and launch for the first combined Advanced Therapy in the EU - MACI
2. Led the development, approval and launch of the first ex- vivo Gene Therapy ever - Strimvelis
3. Co-developed an arthroscopic surgical technique for MACI in the knee.
4. Business & Medical lead in the sale of the Genzyme Cell Therapy franchise (3 products) to a new buyer and led the transfer of all assets and projects.
5. Business & Medical lead in the acquisition of the GSK Rare Diseases Gene Therapy franchise (8 programmes) by Orchard Therapeutics.
6. Led the strategic collaboration & investment in Antion Biosciences by Allogene Corporation.
7. Leading the staged financing of Antion Biosciences.

Selection of Publications:

1. 1.Reduced chondrocyte viability is associated with the use of surgical marker pen ink. Getgood A, McNamara I, Kili S, Bhullar T, Henson F. Am J Sports Med. 2011 Jun;39(6):1270-4
2. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial. Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J, Drogset JO, Emans P, Podskubka A, Tsuchida A, Kili S, Levine D, Brittberg M; SUMMIT study group. Am J Sports Med. 2014 Jun;42(6):1384-94
3. Mechanical testing of fixation techniques for scaffold-based tissue-engineered grafts. Kili S. J Biomed Mater Res B Appl Biomater. 2008 Jan;84(1):298

4. Patient preference and willingness to pay for knee osteoarthritis treatments. Posnett J, Dixit S, Oppenheimer B, Kili S, Mehin N. Patient Prefer Adherence. 2015 Jun 11;9:733-44.
5. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Abou-El-Enein M, Grainger DW, Kili S. Mol Ther. 2018 May 2;26(5):1172-1176.
6. Development and Deployment of Gene Therapies: An ADA-SCID Case Study Kili S, Chaffman M. Cytotherapy 2nd Edition 2020
7. Management of 'out of specification' commercial autologous CAR-T cell products Bersenev A., Kili S. CGT Insights 14 Dec 2018

Summary of involvement with ISCT in the past five years:

- I have been a Member of ISCT since 2015
- I am co-chair of the Business Development and Finance Committee
- I was co-chair of the 2022 Annual ISCT Meeting in San Francisco, where we led the change in the annual meeting format to a more homologous development process.
- I have also attended most annual conferences since 2015 and was a guest speaker at the ISCT annual meetings in Spain 2015, London 2017, Montreal 2018, Paris 2020 (I to I programme), Memphis 2016 (IST N. America)
- I am a member of the ISCT Strategic Advisory Council 2023

Summary of strategic vision for the Global Society:

I believe that the ISCT is perfectly placed to bridge all players in the Cell & Gene Therapy and Tissue Engineering space, from academic research, regulatory support through company involvement and financing all the way to approval, re-imbursement, and life-cycle management. ISCT is uniquely placed to support its members all the way through the therapy development pathway to ensure we develop the best possible solutions for patients.

We have the responsibility to be the conduit for educating, guiding, and informing our membership to create the safest, most efficacious therapies for our patients. This includes developing better informed conversations between all players and improving the way we collaborate on all levels and geographies.

As a development organisation, we have the unique ability to understand the challenges associated with the rapidly developing CGT space and are the 'voice of reason and authority' to external groups seeking a better-balanced understanding of the benefits and risks of utilising cells as medicines.